



A minimal physiologically-based pharmacokinetic model to investigate CNS distribution of metronidazole in ICU patients

Alexia Chauzy, Salim Bouchène, Nicolas Grégoire, William Couet, Olivier Mimos, Sandrine Marchand, Claire Dahyot-Fizelier

► To cite this version:

Alexia Chauzy, Salim Bouchène, Nicolas Grégoire, William Couet, Olivier Mimos, et al.. A minimal physiologically-based pharmacokinetic model to investigate CNS distribution of metronidazole in ICU patients. 39ème Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse (RICAI), Dec 2019, Paris, France. hal-02528416

HAL Id: hal-02528416

<https://hal.science/hal-02528416>

Submitted on 1 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Introduction

- ❖ **Metronidazole** is used to treat brain infections due to anaerobic bacteria. A better understanding of anti-infective drugs **pharmacokinetics (PK) in the CNS** is clearly needed [1, 2].
- ❖ **Minimal Physiologically-Based Pharmacokinetic (PBPK)** modelling approach is valuable to describe drug disposition from a mechanistic standpoint [3]. The alternative minimal PBPK models inherit major physiological attributes of whole-body PBPK models and offer a more rational basis than compartmental models [3].
- ❖ Objective: **To develop a minimal PBPK model in order to characterize metronidazole PK in plasma, brain extracellular fluid (ECF) and ventricular cerebrospinal fluid (CSF) in ICU patients.**

Material & Methods

1. Study design

- Height male patients (median age: 56±12 years, weight = 87±13 kg) were included in the analysis. They received a 30-min IV infusion of 500 mg metronidazole every 8 h.
- CSF samples were collected in 4 patients with high intracranial pressure (ICP) via an external ventricular drainage (EVD) system into the lateral brain ventricles. CSF samples were collected at one occasion at steady state.
- ECF concentrations were measured in 4 other patients with traumatic brain injury by microdialysis technique at one occasion at steady state [2].
- Blood samples were collected simultaneously. Plasma unbound fraction was determined by ultrafiltration and all samples were assayed by LC-MS/MS [2].

2. Minimal PBPK model

- The CNS was represented by 3 compartments: the brain vasculature, the brain ECF and the brain CSF. The rest of the tissues were lumped as a single, perfusion limited and well-stirred tissue compartment (Figure 1).
- The tissue compartments were connected via blood flow (Q) to a plasma pool in a closed-loop format.
- Volumes (V) and blood flows were fixed to their physiological value obtained from literature [4-8].
- Metronidazole elimination was implemented as a total unbound plasma clearance representing both its renal excretion and hepatic metabolism [4].
- Dialysates, collected as fractions during various time intervals, were modeled as the integral over each collection interval [9].




Figure 1. Schematic representation of metronidazole minimal PBPK model: parameters in blue are set to their physiological value or fixed and parameters in black are estimated. The dashed line represents the blood-brain barrier (BBB) and the blood-CSF barrier (BCSFB), PS the clearance distribution across both the BBB and the BCSFB.

- The elimination of metronidazole from the CSF compartment was implemented using EVD flows (Q_{EVD}), determined experimentally, as a covariate.
- As EVD is set when the outflow of CSF ($Q_{CSF-out}$) is obstructed, $Q_{CSF-out} = \text{physiological } Q_{CSF-out} - Q_{EVD}$ in this case.
- Parameters values were estimated using NONMEM 7.4

Results

- The model well described unbound metronidazole PK profiles in plasma, ECF and CSF (Figures 2-3).
- No active transport was implemented in the model but the bidirectional passive diffusion across the BBB was estimated to be almost 10 times more rapid ($PS_{ECF} = 1.56$ L/h) than across the BCSFB ($PS_{CSF} = 0.176$ L/h) (Table 1).

Table 1. Typical estimates for metronidazole pharmacokinetic parameters

Parameter	Typical value (RSE%)	IIV CV% (RSE %)
$K_{P_{res}}$	0.799 (7.4)	-
CL_{tot} (L/h)	7.28 (10.9)	33.6 (47.6)
PS_{ECF} (L/h)	1.56 (42.1)	-
PS_{CSF} (L/h)	0.176 (65.2)	-

RSE: Relative Standard Error ; IIV: Inter-individual Variability ; CV = Coefficient of Variation




Figure 2. Plasma, brain ECF and CSF concentration-time profiles for metronidazole. The circles represent the observed data, the green solid lines the individual predictions and the grey dashed lines the population predictions.




Figure 3: Visual predictive checks of the final PBPK model for unbound metronidazole plasma, ECF and CSF concentrations. Circles represent observed data and the blue-shaded area depicts the 90% prediction interval for 1000 simulated profiles.

Conclusion & Perspectives

- ❖ Metronidazole demonstrated an extensive distribution through BBB and BCSFB, governed by passive diffusion. These results are consistent with the fact that metronidazole is not known to be a substrate of efflux transport systems at the CNS level.
- ❖ The distribution clearance across the BBB (PS_{ECF}) was more rapid than the distribution clearance across the BCSFB (PS_{CSF}), consistent with the larger surface area of BBB relative to the BCSFB [10].
- ❖ The minimal PBPK model will then be used to make simulations in various dosing regimen or/and physiological situations.

References

- [1] Nau et al., Clin Microbiol Rev. 2010
- [2] Frasca et al., Antimicrob Agents Chemother. 2014
- [3] Cao et al., J Pharmacokinet Pharmacodyn. 2012
- [4] de Lange EC, J Pharmacokinet Pharmacodyn. 2013
- [5] Brown et al., Toxicol Ind Health. 1997
- [6] <https://members.simcyp.com/account/tools/PS/>, 2013
- [7] Westerhout et al., J Pharm Sci. 2011
- [8] Ball et al., J Pharm Sci. 2012
- [9] Tunblad et al., Pharm Res. 2004
- [10] Kielbasa et al., Drug Metab Dispos. 2008